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utritional management has
classically been regarded as an
integral part of therapy for chronic
kidney disease (CKD).1,2,S1–S4 Various
dietary constituents are consid-
ered,1,2 but, in the case of CKD‒
mineral and bone disorders
(CKD-MBD), phosphorus (P) load
and hyperphosphatemia have
frequently been the focus of
attention. Higher plasma P levels
(even within the normal range) have
been associated with increased risk
of incident CKD, vascular calcifica-
tion, and cardiovascular morbidity
and mortality.3 Moreover, the role of
P load and/or hyperphosphatemia in
the pathophysiology of secondary
hyperparathyroidism, renal osteo-
dystrophy, left ventricular hyper-
trophy, accelerated progression
of CKD, cardiovascular damage/Correspondence: Jordi Bover, Department
of Nephrology, Fundació Puigvert, C.
Cartagena 340-350, 08025 Barcelona,
Spain. E-mail: jbover@fundacio-puigvert.es
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direct and indirect effects—is sup-
ported by compelling epidemiologic
and experimental evidence, and
biologic plausibility.3,S5,S6
The 2017 Kidney Disease:
Improving Global Outcomes clinical
practice guideline update for CKD-
MBD4 suggested lowering elevated
P levels “toward” the normal range
(Evidence 2C), and proposed that
decisions about P-lowering treat-
ment should be based on progres-
sively or persistently elevated
serum P (not graded). Importantly,
and in marked contrast to the level
of evidence provided by the
recently published National Kidney
Foundation (NKF) guidelines for
nutrition in CKD,2 the Kidney Dis-
ease: Improving Global Outcomes
also suggested limiting dietary
P intake in the treatment of
hyperphosphatemia alone or in
combination with other treatments
(Evidence 2D). Moreover, in both
guidelines it was consideredreasonable to consider P source
(e.g., animal, vegetable, additives)
when making dietary recommen-
dations (not graded, opinion).
Because the level of evidence for
these interventions is still surpris-
ingly disputed,2,4 firm dogmatic
conclusions do not yet seem possi-
ble.S7 Furthermore, the optimal
target for serum P in CKD
remains to be defined, and we
now know that the priority
assigned to lowering serum P
should be individualized and may
differ depending on many factors.5
Nevertheless, all guidelines concur
that randomized clinical trials
(RCTs) are needed to unequivo-
cally demonstrate that treatments
aimed at lowering serum P will
improve hard- or patient-centered
outcomes.4,S2–S4
A few short-term RCTs, some
very old and relatively small, have
evaluated the effect of lowering P
intake or in combination with a low
protein diet in CKD 3‒5D.S8–S11 Ac-
cording to a recent Cochrane re-
view,6 there is limited interventional
evidence that these dietary in-
terventions may positively affect
CKD-MBD,6 and low certainty that
dietary modification makes any dif-
ference to clinical outcomes such as
quality of life, fractures, cardiovas-
cular events, or mortality. Similarly,
in large observational cohorts, di-
etary intake or modification led to
reduced urinary P excretion but did
not significantly change either
serum P or serum fibroblast growth
factor 23 (FGF23) levels, and it
remained unknown whether there
were beneficial clinical oucom-
es.4,S12–S14 Somewhat surprisingly,
the recent NKF guidelines2 recom-
mend (Evidence 1B) adjusting di-
etary P intake to maintain serum P
in the normal range in adults with
CKD 3‒5D. Thus, there is a
remarkable disparity in evidence
level (Evidence 1B vs 2D) compared1845
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Global Outcomes guidelines,2,4 but
the latter nevertheless still consider
dietary P restriction to be an
important standard of practice to
lower elevated P levels, as several
lines of evidence suggest that this
strategy may be effective at least in
hyperphosphatemic advanced CKD or
maintenance hemodialysis (MHD)
patients.4,7 For this reason, a “cease-
fire” in the war on dietary P has
been considered premature,7 and the
need for RCTs to address the effects
of various dietary interventions for
patients with CKD-MBD has been
emphasized.4,7
In this issue of the journal,
Byrne et al.8 analyze, in a pilot
RCT, the short-term (1-month) ef-
ficacy, safety, and tolerability of an
Irish national standard versus
modified low-P diet in 74 MHD
adults, with an average serum P of
>5 mg/dl over the last 3 months
(mean baseline of 5.92 and 6.13
mg/dl, respectively). Of note,
because of the pragmatic nature of
the study, fasting and nonfasting
blood samples were collected,
likely influencing these P levels
and masking the basal effect of the
standard low P diet. The standard
diet restricted pulses, nuts, whole
grains, and other high P foods,
whereas the modified diet replaced
some meat with plant-based vege-
tarian proteins and unsalted pea-
nuts, increased the use of whole-
grain breads and cereals, included
egg whites (very low ratio of P/
protein), and had an increased
focus on the avoidance of P
additives.
At first glance, the results of
this small study may seem some-
what disappointing with regard to
the primary goal of reducing P
and/or FGF23 levels. The non‒
statistically significant small de-
creases in serum P (0.336
and 0.295, respectively) may be
attributable to not only high indi-
vidual variability but also the fact1846that some of the changes would
have increased total P intake.
However, beyond offering helpful
methodologic contributions rele-
vant to the design of future RCTs,
this pragmatic study underlines
the possibility of a significantly
wider food choice (even including
previously “prohibited” products),
without a resultant increase in P or
K levels in an era when patient-
centered approaches to treatments
must be considered. This greater
choice may also improve adher-
ence.S15 Moreover, the modified
diet provides the advantages and
potential pleiotropic beneficial ef-
fects of an effective higher dietary
fiber intake (a significant increase
in bowel movements was
reported).S16
As the authors point out,
nutrition science is moving toward
dietary patterns instead of indi-
vidual food nutrients.S17–S21 In
particular, the Mediterranean,
New Nordic, and the Dietary Ap-
proaches to Stop Hypertension di-
ets have shown beneficial effects in
preventing and managing renal
disease, at least in selected
adherent individuals.S18–S21 Both
the Mediterranean and the Dietary
Approaches to Stop Hypertension
diets overlap in nutritional
composition, encouraging whole
foods such as fruits, vegetables,
pulses, whole grains, and nuts.S17
In addition, these diets restrict
animal protein consumption and
limit processed and fast foods.S17
However, in later CKD stages and
in patients on MHD, the pre-
scribed dietary pattern needs to be
more carefully individualized for
specific nutrients (i.e., P, K, and/or
protein content). For instance,
traditional dietary CKD recom-
mendations limit the intake of
fruits and vegetables because of
their high K content. Nevertheless,
this paradigm is rapidly chang-
ing.S22–S24 A higher fiber content,
acidosis neutralization, decreased PK
absorption, increased magnesium
and vitamin K, and even
improvement in gut dysbiosis and
reductions in inflammation and
oxidative stress, have been
observed with vegetarian diets
(and adequate cooking tech-
niques).S24 In their study,8 the
authors somewhat altered their
standard renal diet toward a
locally adapted Mediterranean di-
etary pattern, retaining the ability
to individualize nutrient re-
strictions without affecting serum
K. Considering that, on a global
scale, there are quite significant
differences in diet compositions
and food availability, such pattern
modifications seem of great inter-
est. Similarly, some modifications
have recently been made to the
New Nordic diet in order to
decrease its P content and absorp-
tion, although these have been
tested for only 1 week in non-
dialysis CKD patients.9
Another important piece of in-
formation provided is the infre-
quently reported phytate-bound P
(significantly higher in the modi-
fied diet). Thus, dietary P sources
were divided into foods with P
that is or is not bound to phytate.
Estimates of dietary P from food
composition tables likely underes-
timate the P content because they
mostly reflect the “natural” P
content of foods, but composition
and absorption may differ accord-
ing to food processing. Moreover,
especially in patients lacking kid-
ney function, it is very important
to consider the bioavailability of P
based on its sources (organic vs.
inorganic).S25 Nephrologists
should be aware of the almost
100% bioavailability of inorganic
P (such as in additives) and the
reduced bioavailability of organic
P in plant foods due to the limited
absorption of phytate-based P in
the human gastrointestinal tract
(owing to the lack of the enzyme
phytase, necessary to degradeidney International Reports (2020) 5, 1845–1847
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Therefore, many of the foods
traditionally labeled as containing
high amounts of P (e.g., beans and
nuts) may be acceptable as protein
sources in view of their low ab-
sorption rate (K permitting). The
potential importance of considering
phytate-bound P is stressed by our
recent study demonstrating that an
intravenous formulation of phytate
(SNF472) significantly attenuated
the progression of coronary artery
and aortic valve calcification in
MHD patients.S26 Dietary regimens
prescribed for MHD patients
reduce the intake of many of the
main phytate-containing foods.S27
In experimental and some human
studies (mostly observational),
phytate has been associated with
several beneficial properties.S27
Beyond the many strengths and
certain weaknesses of the study
(i.e., short-term, heterogeneity of P
measurements), it should be recal-
led that dietary P restriction may
be difficult without compromising
the intake of other nutrients,
especially protein, with the threat
of protein-energy wasting. Protein
intake was lower than recom-
mended in both RCT arms despite
the introduction of some pulses
and nuts. Although the apparent
reduced protein intake may be due
to underreporting, and is unlikely
to be of a different magnitude
when comparing both arms, it may
represent a safety signal that
should be closely followed. In fact,
there is general agreement that,
when targeting dietary P restric-
tion for MHD patients, the focus
should clearly be on P additives
and not protein.7 Therefore,
although the authors describe no
significant differences in protein
intakes, weight, predialysis
urea, or baseline urea reduction
ratio between the 2 groups, inKidney International Reports (2020) 5, 1845–1847upcoming studies it would be most
helpful to closely follow up body
composition and other nutritional
parameters.2 Hopefully, these di-
etary regimens will be used, at
least in selected MHD patients,
over long periods, and it must be
demonstrated that the prescribed
diet is sustainably tailored to pa-
tients’ needs and habits. Finally, it
remains to be proven whether the
addition of P- or K-binders may
improve results without signifi-
cantly interacting with other
drugs, the absorption of other nu-
trients, or the intestinal
flora.S24,S28,S29
Although the differing ap-
proaches and opinions of medical
societies and national guidelines2,4
are puzzling, the need to under-
take challenging RCTs is always
acknowledged. In this context, we
welcome any information, such as
that derived from this pilot RCT,
which may contribute to a more
robust and homogeneous approach
to the cost-effective nutritional
management of CKD 3‒5D.1,8
Rather than enumerating re-
strictions, it may soon be possible
to design individualized dietary
patterns with clearly significant
benefits in terms of clinical out-
comes, or at least patient-related
outcomes.DISCLOSURE
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